

John A Ormiston Mbchb

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6180229/publications.pdf>

Version: 2024-02-01

38
papers

1,717
citations

331670

21
h-index

315739

38
g-index

38
all docs

38
docs citations

38
times ranked

1640
citing authors

#	ARTICLE	IF	CITATIONS
1	Mechanical properties of the drug-eluting bioresorbable magnesium scaffold compared with polymeric scaffolds and a permanent metallic drug-eluting stent. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, E674-E682.	1.7	18
2	Coronary balloon catheter tip damage. A bench study of a clinical problem. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 92, 883-889.	1.7	3
3	Transcatheter Aortic Valve Implantation In Patients With a Large Aortic Annulus. <i>Heart Lung and Circulation</i> , 2018, 27, e11-e14.	0.4	15
4	Bench testing and coronary artery bifurcations: a consensus document from the European Bifurcation Club. <i>EuroIntervention</i> , 2018, 13, e1794-e1803.	3.2	28
5	Long-term serial non-invasive multislice computed tomography angiography with functional evaluation after coronary implantation of a bioresorbable everolimus-eluting scaffold: the ABSORB cohort B MSCT substudy. <i>European Heart Journal Cardiovascular Imaging</i> , 2017, 18, 870-879.	1.2	13
6	A Study of Coronary Bifurcation Shape in a Normal Population. <i>Journal of Cardiovascular Translational Research</i> , 2017, 10, 82-90.	2.4	22
7	Arterial Remodeling After Bioresorbable Scaffolds and Metallic Stents. <i>Journal of the American College of Cardiology</i> , 2017, 70, 60-74.	2.8	51
8	Impact of bifurcation angle and other anatomical characteristics on blood flow – A computational study of non-stented and stented coronary arteries. <i>Journal of Biomechanics</i> , 2016, 49, 1570-1582.	2.1	44
9	Comparison of the Absorbable Polymer Sirolimus-Eluting Stent (MiStent) to the Durable Polymer Everolimus-Eluting Stent (Xience) (from the DESSOLVE I/II and ISAR-TEST-4 Studies). <i>American Journal of Cardiology</i> , 2016, 117, 532-538.	1.6	17
10	A Polylactide Bioresorbable Scaffold Eluting Everolimus for Treatment of Coronary Stenosis. <i>Journal of the American College of Cardiology</i> , 2016, 67, 766-776.	2.8	145
11	Hemodynamics in Idealized Stented Coronary Arteries: Important Stent Design Considerations. <i>Annals of Biomedical Engineering</i> , 2016, 44, 315-329.	2.5	59
12	A computational atlas of normal coronary artery anatomy. <i>EuroIntervention</i> , 2016, 12, 845-854.	3.2	43
13	The value of CT cardiac angiography and CT calcium score testing in a modern cardiology service in New Zealand: a report of a single centre eight-year experience from 5,237 outpatient procedures. <i>New Zealand Medical Journal</i> , 2016, 129, 22-32.	0.5	4
14	Bioabsorbable polymer-coated sirolimus-eluting stent implantation preserves coronary vasomotion: A DESSOLVE II trial substudy. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 86, 1141-1150.	1.7	5
15	A Review of a Regional Primary Percutaneous Coronary Intervention Service, with a Focus on Door to Reperfusion Times: The 2012 Auckland/Northland Experience. <i>Heart Lung and Circulation</i> , 2015, 24, 11-20.	0.4	2
16	Lessons from the real bench: non-BRS. <i>EuroIntervention</i> , 2015, 11, V27-V30.	3.2	8
17	Construction of a Coronary Artery Atlas from CT Angiography. <i>Lecture Notes in Computer Science</i> , 2014, 17, 513-520.	1.3	11
18	First-in-Human Evaluation of a Bioabsorbable Polymer-Coated Sirolimus-Eluting Stent. <i>JACC: Cardiovascular Interventions</i> , 2013, 6, 1026-1034.	2.9	32

#	ARTICLE	IF	CITATIONS
19	Serial Assessment by Optical Coherence Tomography of Early and Late Vascular Responses After Implantation of an Absorbable-Coating Sirolimus-Eluting Stent (from the First-in-Human DESSOLVE I) Tj ETQq1 1 0.784314 rgBT /Ove	1.7	43
20	Transcatheter aortic valve implantation in end-stage renal disease. CKJ: Clinical Kidney Journal, 2012, 5, 247-249.	2.9	4
21	Vascular Compliance Changes of the Coronary Vessel Wall After Bioresorbable Vascular Scaffold Implantation in the Treated and Adjacent Segments. Circulation Journal, 2012, 76, 1616-1623.	1.6	57
22	Comparison of in vivo eccentricity and symmetry indices between metallic stents and bioresorbable vascular scaffolds: Insights from the ABSORB and SPIRIT trials. Catheterization and Cardiovascular Interventions, 2012, 79, 219-228.	1.7	46
23	Comparison of in vivo acute stent recoil between the bioresorbable everolimus-eluting coronary scaffolds (revision 1.0 and 1.1) and the metallic everolimus-eluting stent. Catheterization and Cardiovascular Interventions, 2011, 78, 3-12.	1.7	134
24	IVUS radiofrequency analysis in the evaluation of the polymeric struts of the bioabsorbable everolimus-eluting device during the bioabsorption process. Catheterization and Cardiovascular Interventions, 2010, 75, 914-918.	1.7	18
25	Three-year results of clinical follow-up after a bioresorbable everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB trial. EuroIntervention, 2010, 6, 447-453.	3.2	116
26	First human use of the TAXUs Petal paclitaxel-eluting bifurcation stent. EuroIntervention, 2010, 6, 46-53.	3.2	29
27	The Petal dedicated bifurcation stent. EuroIntervention, 2010, 6, J139-J142.	3.2	4
28	Coronary bifurcation stenting: insights from in vitro and virtual bench testing. EuroIntervention, 2010, 6, J53-J60.	3.2	30
29	A novel paclitaxel-eluting dedicated bifurcation stent: A case report from the first human use Taxus Petal trial. Catheterization and Cardiovascular Interventions, 2009, 73, 637-640.	1.7	8
30	Revascularization for Unprotected Left Main Disease. Journal of the American College of Cardiology, 2009, 54, 1576-1588.	2.8	49
31	Absorbable coronary stents. Lancet, The, 2007, 369, 1839-1840.	13.7	21
32	First-in-human implantation of a fully bioabsorbable drug-eluting stent: The BVS poly-L-lactic acid everolimus-eluting coronary stent. Catheterization and Cardiovascular Interventions, 2007, 69, 128-131.	1.7	118
33	Comparison of in vivo acute stent recoil between the bioabsorbable everolimus-eluting coronary stent and the everolimus-eluting cobalt chromium coronary stent: Insights from the ABSORB and SPIRIT trials. Catheterization and Cardiovascular Interventions, 2007, 70, 515-523.	1.7	137
34	The AST petal dedicated bifurcation stent: First-in-human experience. Catheterization and Cardiovascular Interventions, 2007, 70, 335-340.	1.7	40
35	Bifurcation Coronary Lesions and the "Crush" Technique. Journal of the American College of Cardiology, 2006, 47, 2566-2567.	2.8	3
36	Drug-eluting stents for coronary bifurcations: Bench testing of provisional side-branch strategies. Catheterization and Cardiovascular Interventions, 2006, 67, 49-55.	1.7	162

#	ARTICLE	IF	CITATIONS
37	The FRONTIER Stent Registry. Journal of the American College of Cardiology, 2005, 46, 592-598.	2.8	71
38	Drug-eluting stents for coronary bifurcations: Insights into the crush technique. Catheterization and Cardiovascular Interventions, 2004, 63, 332-336.	1.7	135